GO:0004740 pyruvate dehydrogenase (acetyl-transferring) kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004740 describes the catalytic activity of pyruvate dehydrogenase kinases (PDKs), which phosphorylate the E1 alpha subunit of the pyruvate dehydrogenase complex (PDC) using ATP.
• PDK-mediated phosphorylation inactivates PDC, shifting glucose metabolism away from mitochondrial oxidation and toward glycolysis and lactate production, a hallmark of hypoxic and cancer cells.
• Four PDK isozymes (PDK1-4) are differentially expressed across tissues and respond to metabolic cues such as hypoxia, fasting, and hormonal signals [1, 4].
• PDK dysregulation is implicated in cancer, cardiovascular disease, and metabolic disorders, making it a therapeutic target [6, 7, 8].
• Studying GO:0004740 requires tools such as kinase assays, phospho-specific antibodies, and CRISPR-based gene editing to manipulate PDK genes [5, 3].
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, and library screening services to accelerate research on PDK biology.
Description
Pyruvate dehydrogenase (acetyl-transferring) kinase activity (GO:0004740) is a molecular function that catalyzes the ATP-dependent phosphorylation of the E1 alpha subunit of the pyruvate dehydrogenase complex (PDC), thereby inactivating the complex. This activity is carried out by a family of pyruvate dehydrogenase kinases (PDKs), which serve as critical regulators of the switch between glycolysis and mitochondrial oxidative phosphorylation. The PDC irreversibly converts pyruvate to acetyl-CoA, linking glycolysis to the tricarboxylic acid (TCA) cycle; its inhibition by PDK-mediated phosphorylation is a key mechanism for conserving glucose and adapting to hypoxia [1, 2]. Researchers study GO:0004740 because it sits at the crossroads of cellular energy metabolism, and its dysregulation contributes to cancer, cardiovascular diseases, and metabolic disorders [6, 7, 8]. For example, hypoxia-inducible factor 1 (HIF-1) drives PDK1 expression, which inactivates PDC and reduces mitochondrial oxygen consumption, a metabolic adaptation essential for tumor survival. Similarly, PDK4 is induced in the heart during endotoxemia and contributes to sex-specific cardiac dysfunction. Understanding the regulation and function of PDK enzymes is therefore vital for developing therapies that target metabolic reprogramming. This article provides a comprehensive overview of GO:0004740, covering its definition, biological roles, key genes, disease associations, and experimental approaches. It is intended for researchers seeking to investigate PDK biology using state-of-the-art tools, including CRISPR-based genome editing and functional genomics.
pyruvate dehydrogenase (acetyl-transferring) kinase activity At A Glance
| GO ID | GO:0004740 |
|---|---|
| GO term | pyruvate dehydrogenase (acetyl-transferring) kinase activity |
| Ontology | molecular_function |
| Synonym | PDHK, PDH kinase activity, PDK, pyruvate dehydrogenase kinase activity, pyruvate dehydrogenase kinase (phosphorylating) activity |
| Major function | Phosphorylation and inactivation of the pyruvate dehydrogenase complex E1 alpha subunit |
| Reaction | ATP + L-seryl-[pyruvate dehydrogenase E1 alpha subunit] = ADP + H+ + O-phospho-L-seryl-[pyruvate dehydrogenase E1 alpha subunit] |
| Cofactors | ATP, Mg2+ |
| Regulation | Inhibited by pyruvate, ADP; activated by NADH, acetyl-CoA |
| Cellular location | Mitochondrial matrix |
What Is GO:0004740?
GO:0004740 pyruvate dehydrogenase (acetyl-transferring) kinase activity is defined as the catalysis of the reaction: ATP + L-seryl-[pyruvate dehydrogenase E1 alpha subunit] = ADP + H+ + O-phospho-L-seryl-[pyruvate dehydrogenase E1 alpha subunit]. In simpler terms, it is the enzyme activity that adds a phosphate group to the E1 alpha subunit of the pyruvate dehydrogenase complex using ATP, leading to inhibition of the complex.
Why Is pyruvate dehydrogenase (acetyl-transferring) kinase activity Important in Cell Biology?
GO:0004740 is crucial because it controls the activity of the pyruvate dehydrogenase complex, a gatekeeper enzyme that determines whether pyruvate is oxidized in mitochondria or converted to lactate. By phosphorylating and inhibiting PDC, PDKs allow cells to adapt to hypoxia, conserve glucose for biosynthetic pathways, and maintain redox balance. This function is exploited by cancer cells to support the Warburg effect, and its dysregulation is linked to heart failure, diabetes, and other metabolic diseases [3, 6, 7, 8].
• Regulates the balance between glycolysis and oxidative phosphorylation.
• Enables metabolic adaptation to hypoxia by reducing mitochondrial oxygen consumption.
• Supports cancer cell proliferation by promoting the Warburg effect.
• Plays a role in cardiac energy metabolism and heart failure [3, 4].
• Involved in ferroptosis resistance in cancer cells.
• Contributes to vascular calcification and cardiovascular pathology.
• Target for therapeutic intervention in metabolic disorders and cancer [5, 6].
• Essential for understanding tissue-specific metabolic flexibility.
• Provides a mechanism for glucose conservation during fasting.
• Links mitochondrial function to cellular signaling pathways.
What Happens During pyruvate dehydrogenase (acetyl-transferring) kinase activity?
Substrate recognition and binding
In simple terms: The kinase enzyme finds and grabs the target protein.
PDK enzymes specifically recognize the E1 alpha subunit of the pyruvate dehydrogenase complex (PDC) within the mitochondrial matrix. The binding involves interaction with the lipoyl domain of E1, which positions the serine residue for phosphorylation. This step is regulated by the metabolic state of the cell, with high NADH/NAD+ and acetyl-CoA/CoA ratios enhancing PDK activity.
Phosphorylation of E1 alpha
In simple terms: The kinase adds a phosphate group to the target, turning it off.
Using ATP as a phosphate donor, PDK transfers a phosphoryl group to specific serine residues (Ser293, Ser300, and Ser232 in human E1 alpha) on the E1 alpha subunit. This phosphorylation inactivates the PDC, preventing the conversion of pyruvate to acetyl-CoA. The reaction produces ADP and phospho-E1 alpha, as defined by GO:0004740.
Inactivation of the pyruvate dehydrogenase complex
In simple terms: The whole complex shuts down, so pyruvate is not burned for energy.
Phosphorylation of E1 alpha inhibits the entire PDC, blocking the oxidative decarboxylation of pyruvate. This forces cells to rely on glycolysis and lactate production, even in the presence of oxygen, a phenomenon known as the Warburg effect in cancer [1, 6]. This metabolic shift supports biosynthesis and reduces reactive oxygen species production.
Dephosphorylation and reactivation
In simple terms: Another enzyme removes the phosphate, turning the complex back on.
Pyruvate dehydrogenase phosphatases (PDPs) counteract PDK activity by removing the phosphate groups from E1 alpha, reactivating PDC. The balance between PDK and PDP activity determines the phosphorylation state of PDC and thus the flux of pyruvate into the TCA cycle. This dynamic regulation allows rapid adaptation to changing metabolic demands.
Key Genes Involved in GO:0004740 pyruvate dehydrogenase (acetyl-transferring) kinase activity
The following genes encode the pyruvate dehydrogenase kinases and related regulatory proteins that directly mediate or modulate GO:0004740.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDK1 | Phosphorylates and inactivates PDC; induced by hypoxia via HIF-1 | Key mediator of hypoxic metabolic adaptation and cancer metabolism |
| PDK2 | Ubiquitously expressed; regulates PDC in various tissues | Linked to colorectal tumor growth via OGT-c-Myc axis |
| PDK3 | Testis-specific; may regulate PDC during spermatogenesis | Less studied; potential role in metabolic reprogramming |
| PDK4 | Highly expressed in heart, skeletal muscle, liver; induced by fasting and endotoxemia | Implicated in cardiac dysfunction, ferroptosis resistance, and vascular calcification [4, 7, 8] |
| PDP1 | Pyruvate dehydrogenase phosphatase; reactivates PDC | Counteracts PDK activity; important for metabolic homeostasis |
| PDP2 | Mitochondrial phosphatase; regulates PDC activity | May modulate PDK effects in specific tissues |
| HIF1A | Transcription factor inducing PDK1 under hypoxia | Upstream regulator of PDK1 expression |
| MYC | Oncogene that upregulates PDK2 expression | Drives metabolic reprogramming in cancer |
| OGT | O-GlcNAc transferase; modifies c-Myc to enhance PDK2 expression | Links nutrient sensing to PDK2 regulation |
| PGK1 | Glycolytic enzyme; crotonylation affects PDK1 expression | Connects glycolysis to PDK regulation |
| FGF21 | Hormone that improves mitochondrial bioenergetics; may affect PDK expression | Therapeutic potential in heart failure |
| SLC2A1 | Glucose transporter; indirectly influences PDK via metabolic flux | Marker of glycolytic phenotype |
| LDHA | Lactate dehydrogenase; converts pyruvate to lactate when PDC is inhibited | Downstream effector of PDK-mediated metabolic shift |
| PDHA1 | E1 alpha subunit of PDC; substrate of PDK | Direct target of phosphorylation; mutations cause PDH deficiency |
| PDHB | E1 beta subunit of PDC; forms complex with PDHA1 | Structural component of PDC |
| DLAT | Dihydrolipoamide acetyltransferase; component of PDC | Part of the PDC complex regulated by PDK |
| DLD | Dihydrolipoamide dehydrogenase; component of PDC | Part of the PDC complex |
How Is pyruvate dehydrogenase (acetyl-transferring) kinase activity Regulated?
PDK activity is regulated at multiple levels. Transcriptionally, PDK1 is induced by hypoxia-inducible factor 1 (HIF-1) under low oxygen conditions. PDK2 expression is driven by the OGT-c-Myc axis in colorectal cancer. PDK4 is upregulated by fasting, glucocorticoids, and endotoxemia in a tissue-specific manner. Post-translationally, PDK activity is modulated by metabolites: it is inhibited by pyruvate and ADP, and activated by NADH and acetyl-CoA. Additionally, phosphorylation of PDK itself by other kinases may affect its activity, though specific pathways remain to be fully elucidated. The balance between PDK and PDP activities determines the phosphorylation state of PDC and the metabolic flux of pyruvate.
pyruvate dehydrogenase (acetyl-transferring) kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDK1 | Cancer, hypoxia adaptation | Cancer cell lines with PDK1 knockout or overexpression; xenograft models |
| PDK2 | Colorectal cancer | Colorectal cancer cell lines with PDK2 knockout; OGT-c-Myc axis manipulation |
| PDK4 | Heart failure, endotoxemia, vascular calcification | Cardiomyocyte-specific PDK4 knockout mice; endotoxemia models [4, 8] |
| PDK4 | Ferroptosis resistance | Cancer cells with PDK4 knockout treated with ferroptosis inducers |
| PDHA1 | Pyruvate dehydrogenase deficiency | Patient-derived fibroblasts; knock-in of patient mutations |
Cancer metabolism
PDK enzymes are frequently overexpressed in various cancers, where they promote the Warburg effect by inhibiting PDC and shifting metabolism toward glycolysis [1, 6]. In colorectal cancer, the OGT-c-Myc-PDK2 axis rewires the TCA cycle to support tumor growth. PDK4 suppresses pyruvate oxidation and fatty acid synthesis, conferring resistance to ferroptosis, a form of cell death, in cancer cells. Targeting PDK enzymes is therefore a promising therapeutic strategy for cancer [6, 7].
Cardiovascular disease
PDK4 is a key regulator of cardiac energy metabolism. In heart failure with preserved ejection fraction (HFpEF), FGF21 protects against disease by improving mitochondrial bioenergetics, potentially through modulation of PDK activity. Myocardial PDK4 drives sex-specific cardiac responses to endotoxemia, with male mice showing greater dysfunction. PDK4 also promotes vascular calcification by interfering with autophagic activity and metabolic reprogramming. These findings highlight PDK4 as a therapeutic target in cardiovascular diseases.
Metabolic disorders
Dysregulation of PDK activity contributes to insulin resistance and type 2 diabetes by altering glucose oxidation. PDK4 expression is increased in skeletal muscle during fasting and diabetes, reducing PDC activity and glucose utilization. Modulating PDK activity could improve metabolic health, as suggested by studies showing that Scutellarin rescues mitochondrial damage via the Pdk-Pdc axis.
From pyruvate dehydrogenase (acetyl-transferring) kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDK1 mediate hypoxic metabolic adaptation? | PDK1 knockout cancer cells under hypoxia |
| What is the role of PDK2 in colorectal tumor growth? | PDK2 knockout or overexpression in colorectal cancer cell lines and xenografts |
| How does PDK4 contribute to cardiac dysfunction in endotoxemia? | Cardiomyocyte-specific PDK4 knockout mice subjected to LPS |
| Can PDK4 inhibition sensitize cancer cells to ferroptosis? | PDK4 knockout cancer cells treated with ferroptosis inducers |
| Does PDK4 promote vascular calcification? | Vascular smooth muscle cells with PDK4 knockdown or knockout |
| What is the effect of PDK activation on mitochondrial bioenergetics? | Cells treated with PDK activators or inhibitors, measuring oxygen consumption |
How to Study the pyruvate dehydrogenase (acetyl-transferring) kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Kinase assay | Phosphorylation of E1 alpha by PDK | In vitro validation of PDK activity |
| Phospho-specific Western blot | Levels of phosphorylated PDHA1 | Assessing PDK activity in cells/tissues [1, 4] |
| Seahorse assay | Oxygen consumption rate and extracellular acidification rate | Measuring metabolic shift upon PDK modulation |
| 13C metabolic tracing | Flux of labeled substrates through metabolic pathways | Quantifying pyruvate oxidation and TCA cycle activity |
| CRISPR knockout screen | Genes affecting cell fitness under PDK inhibition | Identifying synthetic lethal targets |
| RNA-seq | Transcriptional changes upon PDK manipulation | Uncovering PDK-regulated gene networks |
| Proteomics | Protein expression and post-translational modifications | Global analysis of PDK signaling |
| Immunoprecipitation | Protein-protein interactions of PDK | Identifying PDK binding partners |
Kinase activity assays
Direct measurement of PDK activity can be performed using recombinant PDK enzymes and the E1 alpha subunit as substrate, with ATP and [γ-32P]ATP, followed by detection of phosphorylated E1 alpha by autoradiography or phospho-specific antibodies. This method quantifies the catalytic activity defined by GO:0004740.
Phospho-specific immunoblotting
Western blotting with antibodies against phospho-Ser293 of PDHA1 is a standard method to assess PDK activity in cells and tissues. This approach has been used to demonstrate increased PDC phosphorylation in hypoxic cancer cells and in cardiac tissue from endotoxemic mice [1, 4].
Metabolic flux analysis
Seahorse extracellular flux analysis and 13C-labeled substrate tracing can measure the impact of PDK activity on glycolysis and oxidative phosphorylation. These techniques have been used to show that PDK4 suppresses pyruvate oxidation and fatty acid synthesis.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that modulate PDK activity or synthetic lethality with PDK inhibition. Such screens have been instrumental in uncovering the OGT-c-Myc-PDK2 axis in colorectal cancer.
How CRISPR Can Be Used to Study GO:0004740 pyruvate dehydrogenase (acetyl-transferring) kinase activity
Knockout
CRISPR-Cas9 knockout of PDK genes (e.g., PDK1, PDK2, PDK4) in cell lines or animal models allows researchers to study loss-of-function phenotypes. For example, PDK1 knockout in cancer cells reduces their ability to survive hypoxia and inhibits tumor growth. EDITGENE offers custom PDK knockout cell lines and mice to accelerate such studies.
Point Mutation
Introducing point mutations in PDK genes or in the phosphorylation sites of PDHA1 (e.g., Ser293Ala) can dissect the specific contribution of phosphorylation to PDC regulation. CRISPR-mediated point mutation models are valuable for understanding the precise molecular mechanisms of GO:0004740.
Knock-in
Knock-in of tagged PDK alleles (e.g., FLAG or GFP) enables visualization and purification of PDK proteins for interaction studies. Additionally, knock-in of patient-derived mutations in PDHA1 can model PDH deficiency and assess the impact on PDK-mediated regulation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of PDK genes can mimic the elevated PDK levels seen in cancer and metabolic diseases. Overexpression models are useful for studying the Warburg effect and testing PDK inhibitors [6, 7].
How EDITGENE Supports pyruvate dehydrogenase (acetyl-transferring) kinase activity Research
Researchers studying pyruvate dehydrogenase (acetyl-transferring) kinase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or therapeutic response. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell and animal models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for pyruvate dehydrogenase (acetyl-transferring) kinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PDK4 Knockout HEK293 Cell Line | EDJ-KQ447 | Human | 5166 | Details Get a Quote |
| BCKDK Knockout HEK293 Cell Line | EDJ-KQ1127 | Human | 10295 | Details Get a Quote |
| PDK1 Knockout HEK293 Cell Line | EDJ-KQ1504 | Human | 5163 | Details Get a Quote |
| PDK2 Knockout HEK293 Cell Line | EDJ-KQ3278 | Human | 5164 | Details Get a Quote |
| PDK3 Knockout HEK293 Cell Line | EDJ-KQ5434 | Human | 5165 | Details Get a Quote |
| BCKDK Knockout HCT 116 Cell Line | EDJ-KQ18979 | Human | 10295 | Details Get a Quote |
| PDK4 Knockout A-549 Cell Line | EDJ-KQ20073 | Human | 5166 | Details Get a Quote |
| PDK4 Knockout HCT 116 Cell Line | EDJ-KQ20075 | Human | 5166 | Details Get a Quote |
| PDK4 Knockout HeLa Cell Line | EDJ-KQ20076 | Human | 5166 | Details Get a Quote |
| PDK1 Knockout A-549 Cell Line | EDJ-KQ21121 | Human | 5163 | Details Get a Quote |
| PDK1 Knockout HCT 116 Cell Line | EDJ-KQ21122 | Human | 5163 | Details Get a Quote |
| PDK1 Knockout HeLa Cell Line | EDJ-KQ21123 | Human | 5163 | Details Get a Quote |
| BCKDK Knockout A-549 Cell Line | EDJ-KQ20324 | Human | 10295 | Details Get a Quote |
| BCKDK Knockout HeLa Cell Line | EDJ-KQ20326 | Human | 10295 | Details Get a Quote |
| PDK2 Knockout HCT 116 Cell Line | EDJ-KQ23446 | Human | 5164 | Details Get a Quote |
Displaying Records 1 To 15 Of 23 Records
Frequently Asked Questions About pyruvate dehydrogenase (acetyl-transferring) kinase activity
What is pyruvate dehydrogenase (acetyl-transferring) kinase activity?
It is the enzyme activity (GO:0004740) that phosphorylates the E1 alpha subunit of the pyruvate dehydrogenase complex using ATP, thereby inactivating the complex and reducing pyruvate oxidation.
What genes are involved in pyruvate dehydrogenase (acetyl-transferring) kinase activity?
The main genes are PDK1, PDK2, PDK3, and PDK4, which encode the pyruvate dehydrogenase kinases. Other related genes include PDHA1 (the substrate), PDP1/PDP2 (phosphatases), and upstream regulators like HIF1A and MYC [1, 6].
How is pyruvate dehydrogenase kinase activity regulated?
PDK activity is regulated transcriptionally by hypoxia (HIF-1), oncogenes (c-Myc), and hormones, and post-translationally by metabolites such as NADH, acetyl-CoA, pyruvate, and ADP [1, 6].
What diseases are associated with pyruvate dehydrogenase kinase?
PDK dysregulation is linked to cancer, heart failure, vascular calcification, diabetes, and metabolic disorders [1, 3, 4, 6, 7, 8].
What is the role of PDK4 in the heart?
PDK4 is highly expressed in the heart and contributes to cardiac dysfunction during endotoxemia and heart failure by inhibiting PDC and altering energy metabolism.
How can I study pyruvate dehydrogenase kinase activity in the lab?
Common methods include kinase assays, phospho-specific Western blots for PDHA1, Seahorse metabolic flux analysis, and CRISPR-based genetic screens [1, 5, 6].
What CRISPR models are available for PDK research?
EDITGENE offers PDK knockout, point mutation, knock-in, and overexpression models, as well as CRISPR library screening and bioinformatics services.
Why is PDK a target for cancer therapy?
PDK inhibition forces cancer cells to rely on oxidative phosphorylation, which can increase reactive oxygen species and induce cell death, making it a promising therapeutic strategy [1, 6, 7].
What is the Warburg effect and how does PDK contribute?
The Warburg effect is the preference of cancer cells for glycolysis over oxidative phosphorylation. PDK contributes by inhibiting PDC, thereby blocking pyruvate entry into the TCA cycle.
Can PDK activity be measured in patient samples?
Yes, phospho-PDHA1 levels can be assessed in tissue lysates by Western blot or immunohistochemistry, providing a readout of PDK activity [1, 4].
Conclusion
GO:0004740 pyruvate dehydrogenase (acetyl-transferring) kinase activity is a central regulator of cellular energy metabolism, controlling the switch between glycolysis and oxidative phosphorylation. Its dysregulation is implicated in cancer, cardiovascular disease, and metabolic disorders, making it an attractive therapeutic target. Advances in CRISPR genome editing and functional genomics are enabling precise interrogation of PDK biology, and EDITGENE is committed to providing the tools and services needed to accelerate this research.
References
- 1. Kim JW et al.. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.. Cell Metab 3(3):177-85 PMID: 16517405
- 2. Guo Z et al.. 2024. Hypoxia-induced downregulation of PGK1 crotonylation promotes tumorigenesis by coordinating glycolysis and the TCA cycle.. Nat Commun 15(1):6915 PMID: 39134530
- 3. Zhang K et al.. 2025. FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice.. Nat Commun 16(1):1661 PMID: 39955281
- 4. Yap JQ et al.. 2025. Myocardial pyruvate dehydrogenase kinase 4 drives sex-specific cardiac responses to endotoxemia.. JCI Insight 10(13) PMID: 40626362
- 5. Sheng N et al.. 2023. Scutellarin Rescued Mitochondrial Damage through Ameliorating Mitochondrial Glucose Oxidation via the Pdk-Pdc Axis.. Adv Sci (Weinh) 10(32):e2303584 PMID: 37750289
- 6. Wang H et al.. 2024. The OGT-c-Myc-PDK2 axis rewires the TCA cycle and promotes colorectal tumor growth.. Cell Death Differ 31(9):1157-1169 PMID: 38778217
- 7. Song X et al.. 2021. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis.. Cell Rep 34(8):108767 PMID: 33626342
- 8. Ma WQ et al.. 2020. PDK4 promotes vascular calcification by interfering with autophagic activity and metabolic reprogramming.. Cell Death Dis 11(11):991 PMID: 33203874
